© 2022 MJH Life Sciences and Pharmacy Times. All rights reserved.
© 2022 MJH Life Sciences™ and Pharmacy Times. All rights reserved.
January 14, 2022
Bradley J. Monk, MD, FACS, FACOG, leads the discussion on upcoming combination therapy regimens with PARP inhibitors for the treatment of ovarian cancer.
January 07, 2022
Drs Bradley J. Monk, Sarah Hayward, and Jennifer MacDonald comment on monitoring and managing adverse events with PARP inhibitor therapy in patients with ovarian cancer in the frontline maintenance setting.
Bradley J. Monk, MD, FACS, FACOG, and Jennifer MacDonald, PharmD, BCOP, share insight on improving outcomes and optimizing therapy with PARP inhibitors in the frontline maintenance setting for ovarian cancer.
Dr Sarah Hayward leads the discussion on optimal approaches to influence patient compliance to PARP inhibitor therapy for frontline maintenance in ovarian cancer.
Bradley J. Monk, MD, FACS, FACOG, leads the discussion on the efficacy of currently approved PARP inhibitors used in the first-line maintenance setting for ovarian cancer and how pharmacists can help patients overcome access barriers.
Sarah Hayward, PharmD, BCOP, leads the discussion on common toxicities and when to create dose adjustments for first-line maintenance therapy in patients with ovarian cancer.